Shi Gao Liu
Plus aucun poste en cours
Fortune : 4 M $ au 31/03/2024
Profil
Shi Gao Liu is the founder of two companies, Henlius Biopharmaceuticals, Inc. and Shanghai Henlius Biotech, Inc., both founded in 2009.
He held the title of President & Chief Executive Officer at Henlius Biopharmaceuticals, Inc. and Chief Executive Office & Executive Director at Shanghai Henlius Biotech, Inc. Dr. Liu received a doctorate degree from Purdue University in 1991.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 30/06/2023 | 2 410 695 ( 1,48% ) | 4 M $ | 31/03/2024 |
Anciens postes connus de Shi Gao Liu
| Sociétés | Poste | Fin |
|---|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Founder | 30/09/2020 |
Henlius Biopharmaceuticals, Inc.
 Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Chief Executive Officer | - |
Formation de Shi Gao Liu
| Purdue University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHANGHAI HENLIUS BIOTECH, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Henlius Biopharmaceuticals, Inc.
Henlius Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Henlius Biopharmaceuticals, Inc. focuses on development and commercialization of mAb-based therapeutics biosimilars and biobetter for malignant tumors and auto-immune diseases. The company was founded by Scott Liu and Paul Liu in 2009 and is headquartered in Fremont, CA. | Health Technology |
